Arthramid joint care is revolutionizing veterinary medicine by restoring synovial health and transforming the way joint diseases are managed in horses and dogs. With growing research through 2025, Contura Vet continues to strengthen the scientific foundation behind 2.5% iPAAG and its cross-species therapeutic potential.

The Evolution of Arthramid Joint Care

Over the past decade, Arthramid joint care—based on intra-articular 2.5% polyacrylamide hydrogel (2.5% iPAAG)—has gained remarkable global adoption in both equine and canine practice. More than 300,000 horses and countless dogs have received treatment, showing long-lasting improvement even after a single injection.

Unlike corticosteroids that only offer short-term symptom relief, 2.5% iPAAG works differently. It integrates into the synovial membrane, improving its structure and function. This restoration of joint mechanics promotes long-term comfort and mobility.

Research Expanding Through 2025

Contura Vet’s research commitment ensures that Arthramid joint care continues to evolve with science. By the end of 2025, multiple peer-reviewed studies will cover equine, canine, and human applications.

Key highlights include:

• International Cartilage Regeneration & Joint Preservation Society World Congress (October):
  • Effects of 2.5% iPAAG in equine osteoarthrosis models
  • Synovial response and structural changes after hydrogel treatment
  • Shear stiffness studies of the equine synovial membrane
• American College of Veterinary Surgeons Surgery Summit (October):
  • Evaluation of 2.5% iPAAG in canine elbow OA
  • Owner-reported outcomes showing tolerance and OA improvement
  • Translational research linking equine and canine studies
• AAEP Convention (December):
  • The impact of 2.5% iPAAG on equine performance and recovery
  • Veterinary innovation and long-term retrospective analyses
  • Comparative studies involving more than 1,700 horses

Translational Impact Across Species

The expanding research pipeline demonstrates how Arthramid joint care bridges veterinary and human medicine under the One Health approach. Studies show that 2.5% iPAAG not only relieves symptoms but may also modify disease progression by restoring normal synovial function.

“Many companies stop research after reaching the market,” says Michaela Arcaro, VP of Operations at Contura Vet. “But we continue investing in science to ensure veterinarians and physicians have high-quality data that supports evidence-based care.”

Through ongoing collaboration across species, Arthramid joint care is helping redefine osteoarthritis management—from early diagnosis to long-term recovery—improving outcomes for both animals and humans.